Eli Lilly to present Baricitinib’s results for Juvenile Idiopathic Arthritis from its Phase III safety and efficacy study at EULAR 2022

EULAR 2022: A look at Lilly’s Baricitinib Late Breaking (LBA) Abstract presentation

This year, the EULAR (European Congress of Rheumatology) 2022 will be held virtually and in-pace in Copenhagen, which will be providing the first-ever hybrid congress experience. Among the access presentations planned for EULAR 2022, we have chosen something of supreme importance.


Lilly’s Baricitinib Late Breaking (LBA) Abstract

For adult patients with moderate to severe active Rheumatoid arthritis (RA), Olumiant (baricitinib) which is a Janus Kinase (JAK) inhibitor is used for the treatment. It is prominently used in patients who have inadequate responses to one or more TNF blockers. 

The Phase III efficacy and safety study of baricitinib for JIA treatment data will be presented by Lilly. It is basically a group of diseases characterized by immune-mediated chronic arthritis, which often requires treatment with conventional synthetic or biologic disease-modifying antirheumatic drugs. The main intention of the study was to look into baricitinib efficacy and safety in pediatric patients with JHA and a poor response to the conventional or biologic-DMARDs.

The Phase III of the JUVE-BASIS trial was carried out at different locations and this year in January it was completed. The goal of this study was to estimate the safety and efficacy of the oral dosage of baricitinib for the treatment of JIA patients, targeting the patients of age groups 2-17 specifically.

Conclusion

For the treatment of JIA patients, NICE has already recommended JAK inhibitors. The United States FDA has also approved Pfizer’s Xelijanz (tofacitinib) for JIA treatment, which is the only approved JAK inhibitor for JIA patients. The approval for the treatment of JIA patients with baricitinib will pose a competitive challenge to the alre[dy approved JAK inhibitors, tofacitinib, in the JIA space. If so happens barticinib will be the second JAK inhibitor to be recommended in the JIA treatment space with an acceptable safety profile.

Visit to know more @ Juveline Idiopathic Arthritis market

For more detailed information visit: https://www.delveinsight.com/eular-conference/eular-2022

Some of the Latest Abstracts launched in EULAR 2022:

 

Report Offerings by DelveInsight:

 

Diagnostic Imaging Equipment Market

Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases.

 

Invasive Candidiasis Market

"DelveInsight’s ‘Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027’ report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises North America, Europe, APAC, and RoW.

 

Sialidosis Market 

DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology as well as the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Filgrastim Biosimilar Insight

DelveInsight’s, “Filgrastim Biosimilar Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

 

Pain Management Devices Market

Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027.

 

To know more about our Competitive Services, Click here: Pharma Competitive Intelligence


Also, take a glance at our Blog Section:


Comments

Post a Comment

Popular posts from this blog

Innovations in Surgical Cameras and Their Impact on Healthcare

Image
  The Evolution of Surgical Cameras Surgical cameras have revolutionized modern medicine by enabling detailed visualization during procedures that were once only performed through open surgeries. The evolution of these cameras has been marked by advancements in technology, allowing for higher resolution images and improved maneuverability within the surgical field. From bulky, early prototypes to sleek, high-definition cameras, their development has significantly enhanced surgical precision and patient outcomes. Types of Surgical Cameras Various types of surgical cameras cater to different medical needs. Endoscopy cameras, for instance, are crucial in minimally invasive surgeries (MIS), providing clear visualization inside the body without large incisions. These cameras come in rigid and flexible forms, each suited for specific anatomical areas and procedures. The market for endoscopy cameras, a subset of the global surgical camera market , continues to grow as demand increases fo...
Read more

What is Chronic Wounds and why is its market booming?

Image
The Chronic Wounds market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Wounds pipeline products will significantly revolutionize the Chronic Wounds market dynamics.    DelveInsight’s “ Chronic Wounds Market Insights , Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Wounds, historical and forecasted epidemiology as well as the Chronic Wounds market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Chronic Wounds market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of...
Read more

Condom Market Report 2028: Market Size, Trends, and Forecast

Image
  What is a Condom? A condom is a barrier contraceptive device made of latex, polyurethane, or lambskin that is designed to prevent the transmission of sexually transmitted infections (STIs) and unintended pregnancies. It is one of the most widely used methods of protection during sexual activity. What is the market for Global Condom? The global Condom market is robust and continues to witness significant growth. This market is driven by the dual benefits of protection against STIs and contraception. Moreover, the market is evolving with the introduction of innovative and user-friendly condom designs, attracting a broader demographic. What are the Condom market drivers? The Condom Market Drivers are illustrated as follows- 1. Public Health Initiatives: Public health campaigns promoting safe sex and the prevention of STIs and unintended pregnancies drive condom use. 2. Increasing Awareness: Growing awareness of the importance of safe sex practices and the benefits of condom use...
Read more